Liu Cao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Liu Cao has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Chunmei Li
Centre for Infection and Immunity Study (CIIS), School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen, China
2 shared publications - Deyin Guo
State Key Laboratory of Respiratory Disease National Clinical Research Center for Respiratory Disease Guangzhou Institute of Respiratory Health the First Affiliated Hospital of Guangzhou Medical University Guangzhou China
2 shared publications Yanxi Ji
2 shared publicationsBixia Ke
Center for Disease Control and Prevention of Guangdong Province, Guangzhou 511430, Guangdong, China
1 shared publicationChunyan Wu
1 shared publicationChuwen Lin
Centre for Infection and Immunity Studies (CIIS), School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, Guangdong, China
1 shared publication
Latest Publications
- Open Access
- 1 August 2026
- Published by KEAI Publishing in Virologica Sinica
- Vol. 41 (4) , 820-831
The antiviral role of TRIM25 in mammalian embryonic stem cells
- 1 August 2026
- Published by KEAI Publishing in Virologica Sinica
- Vol. 41 (4) , 820-831
Open AccessThe antiviral role of TRIM25 in mammalian embryonic stem cells
- Open Access
- 7 September 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (661) , eabm7621
The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus driving the ongoing coronavirus disease 2019 (COVID-19) pandemic, continues to rapidly evolve. Because of the limited efficacy of vaccination in prevention of SARS-CoV-2 transmission and continuous emergence of variants of concern (VOCs), orally bioavailable and broadly efficacious antiviral drugs are urgently needed. Previously, we showed that the parent nucleoside of remdesivir, GS-441524, has potent anti–SARS-CoV-2 activity. Here, we report that esterification of the 5′-hydroxyl moieties of GS-441524 markedly improved antiviral potency. This 5′-hydroxyl-isobutyryl prodrug, ATV006, demonstrated excellent oral bioavailability in rats and cynomolgus monkeys and exhibited potent antiviral efficacy against different SARS-CoV-2 VOCs in vitro and in three mouse models. Oral administration of ATV006 reduced viral loads and alleviated lung damage when administered prophylactically and therapeutically to K18-hACE2 mice challenged with the Delta variant of SARS-CoV-2. These data indicate that ATV006 represents a promising oral antiviral drug candidate for SARS-CoV-2.
- 7 September 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (661) , eabm7621
Open AccessThe adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus driving the ongoing coronavirus disease 2019 (COVID-19) pandemic, continues to rapidly evolve. Because of the limited efficacy of vaccination in prevention of SARS-CoV-2 transmission and continuous emergence of variants of concern (VOCs), orally bioavailable and broadly efficacious antiviral drugs are urgently needed. Previously, we showed that the parent nucleoside of remdesivir, GS-441524, has potent anti–SARS-CoV-2 activity. Here, we report that esterification of the 5′-hydroxyl moieties of GS-441524 markedly improved antiviral potency. This 5′-hydroxyl-isobutyryl prodrug, ATV006, demonstrated excellent oral bioavailability in rats and cynomolgus monkeys and exhibited potent antiviral efficacy against different SARS-CoV-2 VOCs in vitro and in three mouse models. Oral administration of ATV006 reduced viral loads and alleviated lung damage when administered prophylactically and therapeutically to K18-hACE2 mice challenged with the Delta variant of SARS-CoV-2. These data indicate that ATV006 represents a promising oral antiviral drug candidate for SARS-CoV-2.